Metis Global Partners LLC bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,850 shares of the specialty pharmaceutical company’s stock, valued at approximately $271,000.
A number of other institutional investors and hedge funds have also recently made changes to their positions in JAZZ. UMB Bank n.a. lifted its holdings in shares of Jazz Pharmaceuticals by 70.4% in the first quarter. UMB Bank n.a. now owns 271 shares of the specialty pharmaceutical company’s stock worth $40,000 after acquiring an additional 112 shares during the last quarter. Huntington National Bank lifted its holdings in shares of Jazz Pharmaceuticals by 37.9% in the fourth quarter. Huntington National Bank now owns 324 shares of the specialty pharmaceutical company’s stock worth $52,000 after acquiring an additional 89 shares during the last quarter. U.S. Capital Wealth Advisors LLC bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth about $53,000. IFP Advisors Inc lifted its holdings in shares of Jazz Pharmaceuticals by 26.5% in the fourth quarter. IFP Advisors Inc now owns 358 shares of the specialty pharmaceutical company’s stock worth $64,000 after acquiring an additional 75 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in shares of Jazz Pharmaceuticals by 138.1% in the fourth quarter. Quadrant Capital Group LLC now owns 512 shares of the specialty pharmaceutical company’s stock worth $82,000 after acquiring an additional 297 shares during the last quarter. Institutional investors own 87.34% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on JAZZ shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jazz Pharmaceuticals in a report on Monday, July 10th. Needham & Company LLC reiterated a “buy” rating and issued a $226.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $204.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday. Royal Bank of Canada dropped their price objective on shares of Jazz Pharmaceuticals from $203.00 to $201.00 and set an “outperform” rating for the company in a report on Thursday. Finally, StockNews.com started coverage on shares of Jazz Pharmaceuticals in a report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $212.00.
Insider Buying and Selling at Jazz Pharmaceuticals
In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 1,600 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $127.98, for a total transaction of $204,768.00. Following the completion of the sale, the executive vice president now owns 32,826 shares of the company’s stock, valued at approximately $4,201,071.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Neena M. Patil sold 1,600 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $127.98, for a total transaction of $204,768.00. Following the completion of the sale, the executive vice president now owns 32,826 shares of the company’s stock, valued at approximately $4,201,071.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Renee D. Gala sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $131.75, for a total transaction of $790,500.00. Following the sale, the chief financial officer now directly owns 35,978 shares of the company’s stock, valued at approximately $4,740,101.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 7,726 shares of company stock valued at $1,011,386. 4.40% of the stock is currently owned by company insiders.
Jazz Pharmaceuticals Stock Performance
NASDAQ:JAZZ opened at $139.35 on Friday. The company has a market capitalization of $8.80 billion, a PE ratio of -88.76, a P/E/G ratio of 1.05 and a beta of 0.73. The company has a 50 day simple moving average of $128.06 and a two-hundred day simple moving average of $136.98. The company has a debt-to-equity ratio of 1.61, a quick ratio of 2.32 and a current ratio of 3.18. Jazz Pharmaceuticals plc has a fifty-two week low of $120.64 and a fifty-two week high of $163.31.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported $3.20 earnings per share for the quarter, missing analysts’ consensus estimates of $3.58 by ($0.38). The firm had revenue of $892.81 million for the quarter, compared to analyst estimates of $898.11 million. Jazz Pharmaceuticals had a negative net margin of 2.30% and a positive return on equity of 24.47%. Research analysts anticipate that Jazz Pharmaceuticals plc will post 14.73 earnings per share for the current year.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.
Read More
- Five stocks we like better than Jazz Pharmaceuticals
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- MarketBeat Week in Review – 8/7 – 8/11
- What Does Downgrade Mean in Investing?
- 3 Retailers To Watch Closely Next Week
- What is the Hang Seng index?
- Investing in Coffee: 3 Great Strategies to Consider
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
